Note 9. Share-based Compensation:

During the quarter ended September 30, 2026, no stock options were granted. During the quarter ended September 30, 2025, the Company granted 0.9 million stock options at a weighted average grant price of $53.60 and a weighted average fair value of $18.86. During the quarters ended September 30, 2026 and 2025, the Company granted 0.7 million and 0.6 million restricted stock units at a weighted average fair value of $72.39 and $53.60, respectively. During the quarters ended September 30, 2026 and 2025, the Company did not grant restricted common stock awards.

Stock options for 0.9 million and 1.4 million shares of common stock with total intrinsic values of $21.1 million and $18.8 million were exercised during the quarters ended September 30, 2026 and 2025, respectively.

Stock-based compensation expense, inclusive of payroll taxes, of $14.0 million and $11.7 million was included in Selling, general and administrative expenses for the quarters ended September 30, 2026 and 2025, respectively. Additionally, the Company recognized $0.4 million of stock-based compensation costs, inclusive of payroll taxes, in Cost of sales for the quarters ended September 30, 2026 and 2025. As of September 30, 2026, there was $66.8 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 1.7 years.